(Q37271761)

English

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

scientific article published on 30 June 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

chronic obstructive pulmonary disease

0 references

1 reference

ORCID Public Data File 2021

author name string

Christine R Jenkins

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Paul W Jones

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peter M A Calverley

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bartolome Celli

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Julie A Anderson

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Gary T Ferguson

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Julie C Yates

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lisa R Willits

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jörgen Vestbo

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

30 June 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Respiratory Research

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

59

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

The severity of airways obstruction as a determinant of treatment response in COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

6 September 2017

The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

6 September 2017

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

6 September 2017

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

6 September 2017

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

The TORCH (towards a revolution in COPD health) survival study protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714501

3 September 2018

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Updated 2003

1 reference

https://pubmed.ncbi.nlm.nih.gov/19566934

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1465-9921-10-59

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37271761&oldid=2200110119"